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standing of how proteins such as AcbA 
are secreted. Several different path-
ways can mediate the unconventional 
secretion of cytosolic proteins (Nickel, 
2005). One such pathway is direct trans-
location across the plasma membrane 
via ATP-driven ABC transporters, but 
data from Kinseth et al. (2007) argue 
against this route for AcbA. An alterna-
tive possibility is depicted in Figure 1. In 
this scenario, AcbA is transported from 
the cytosol into the internal vesicles 
of endosomal multivesicular bodies 
(MVBs), which subsequently fuse with 
the plasma membrane to release the 
internal vesicles as exosomes. GrpA 
would be needed at some stage of this 
process. Support for such a mecha-
nism comes from the finding that AcbA 
can be visualized in association with an 
endosomal compartment underneath 
the plasma membrane (Adam Kuspa, 
personal communication).
If we assume that GrpA is required 
for MVBs to fuse with the plasma 
membrane, two models could explain 
this requirement. In the first model 
(Figure 1A), GrpA shuttles between 
the Golgi and the plasma membrane 
and has distinct functions at the two 
locations. At the plasma membrane, 
GrpA would operate as part of the 
MVB fusion machinery. This idea 
raises the exciting possibility that 
GRASPs act as a go-between to 
coordinate the activities of the con-
ventional and unconventional secre-
tory pathways. In the second model 
(Figure 1B), GrpA operates exclu-
sively at the Golgi and is selectively 
required for the biosynthetic trans-
port of a plasma membrane compo-
nent of the MVB fusion machinery. 
Hence, further insight into Dictyoste-
lium sporulation may illuminate the 
role of GRASPs in protein transport. 
Of course, variations on these mod-
els can be envisioned. For example, 
GrpA function might be required at 
the step of AcbA internalization into 
MVBs or for an unconventional secre-
tory pathway that is independent of 
MVBs. Regardless, the elegant work 
of Kinseth et al. (2007) has revealed a 
surprising link between conventional 
and unconventional secretion.
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Obesity is becoming so prevalent 
in Western populations that it may 
already be adversely affecting mor-
tality rates (Adams et al., 2006). It is 
a disorder of energy metabolism that 
predisposes to diabetes, hyperten-
sion, and hyperlipidemia, diseases 
characterized by insulin resistance 
and complicated by atherosclerosis 
(Semenkovich, 2006). Availability of 
nutrient-dense food and the accep-
tance of exercise as optional may 
explain why adiposity is increasing 
in populations. Yet, there is a lim-
ited understanding of the striking 
differences between individuals in 
metabolic rate and susceptibility to 
obesity-associated disease. Once 
obesity is established, therapies 
are seldom successful. Treatment is 
focused on manifestations such as 
elevated blood sugar, blood pressure, 
and cholesterol, instead of the under-
lying disorder of energy metabolism.
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Obesity, insulin resistance, and diabetes are related disorders of energy metabolism for 
which therapies are suboptimal. In this issue of Cell, Lee et al. (2007) demonstrate in mice 
that bone regulates the insulin/glucose axis and energy metabolism, providing a new 
framework for approaching common disorders of bioenergetics.
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In this issue, Lee and colleagues 
(2007) make the surprising observa-
tion that bone, a tissue not previously 
thought to impact bioenergetics, can 
affect adiposity, glucose metabolism, 
and insulin sensitivity. People with 
obesity and diabetes are known to 
have abnormalities of bone metabo-
lism. Increased adiposity is a risk fac-
tor for fracture in children (Goulding 
et al., 2001), and diabetics are prone 
to fracture, although there is little evi-
dence that they are predisposed to 
osteoporosis (Schwartz et al., 2001). 
However, the rate of bone turnover is 
decreased in diabetics as reflected 
by diminished expression of biomark-
ers of bone resorption and formation, 
including osteocalcin, an osteoblast-
specific protein (Gerdhem et al., 
2005). Common thinking holds that 
the decrease in osteoblast activity (the 
cells that build bone) results from the 
consequences of diabetes including 
hyperglycemia, and decreased levels 
or effectiveness of insulin and IGF-1 
(Inaba, 2004). Lee et al. (2007) now 
present data to challenge this notion 
and raise the provocative concept 
that the reduction in osteoblast func-
tion may contribute to obesity and 
glucose intolerance. In this scenario, 
a vicious cycle would exist in which 
the metabolic sequelae of diabetes 
suppress osteoblast function, lead-
ing to diminished osteocalcin bioac-
tivity, which in turn further aggravates 
obesity and insulin resistance.
Several lines of evidence from Lee 
and colleagues support the notion 
that osteoblasts can alter energy 
metabolism. Mice with genetic inac-
tivation of Esp, which encodes the 
osteoblast protein tyrosine phospha-
tase OST-PTP, have numerous met-
abolically desirable characteristics: 
increased proliferation of pancreatic 
beta cells, increased insulin secre-
tion, lower blood sugar, increased 
insulin sensitivity, decreased vis-
ceral fat, and increased energy 
expenditure (Figure 1). Animals with 
Esp deficiency are protected from 
both hyperphagia-induced and diet-
induced obesity. Part of their meta-
bolic phenotype may be explained by 
increased production of adiponectin, 
a protein secreted from adipocytes 
that increases fatty acid catabolism. 
Transgenic mice that overexpress 
Esp in osteoblasts have decreased 
pancreatic beta cell proliferation and 
display hyperglycemia and insulin 
resistance. Coculture experiments 
demonstrate that Esp-deficient 
osteoblasts increase insulin expres-
sion in pancreatic islets and increase 
adiponectin expression in adipo-
cytes, suggesting that Esp controls 
the bioactivity of a secreted protein 
that influences pancreatic beta cells 
as well as adipocytes.
Osteocalcin may be that protein. 
Osteocalcin-deficient mice are 
obese with decreased beta cell pro-
liferation, greater insulin resistance, 
and decreased energy expenditure, 
the opposite of Esp null mice. Osteo-
calcin increases insulin and adipo-
nectin expression. In perhaps the 
most compelling experiment of their 
paper, Lee et al. (2007) show that 
Esp null mice that are also heterozy-
gous for osteocalcin deficiency are 
devoid of the metabolically benefi-
cial characteristics seen in Esp null 
mice that are wild-type for osteocal-
cin. This result places the intracel-
lular phosphatase encoded by Esp 
and the secreted protein osteocal-
cin in the same pathway linking the 
skeleton and bioenergetics.
The relationship between Esp and 
osteocalcin does not appear to involve 
effects on osteocalcin production or 
clearance because osteocalcin levels 
are normal in Esp null mice. Osteo-
calcin undergoes a posttranslational 
modification consisting of the γ-car-
boxylation of glutamic acid residues. 
Osteocalcin in mice that lack Esp 
appears to be modified to a lesser 
extent than it is in wild-type mice. 
Treatment of osteoblasts with war-
farin, an inhibtor of γ-carboxylation, 
resulted in increased adiponectin 
expression in coculture experiments 
using adipocytes, and uncarboxyl-
ated (but not carboxylated) osteo-
calcin increased insulin expression in 
pancreatic islet cells.
If these observations extend to 
man, they carry several implications. 
First, pharmacological inhibition of the 
Esp gene product could have numer-
ous benefits including the preserva-
tion of beta cell function, decreased 
adiposity, and the advantages of 
inhibiting a protein with limited tis-
sue distribution. Second, warfarin is 
commonly used to decrease the risk 
of thrombosis. Although this therapy 
is not generally thought to affect 
energy metabolism, a systematic 
assessment of glucose metabolism 
and adiposity in these patients could 
reveal unexpected effects mediated 
by osteocalcin. Consistent with this 
notion, γ-carboxylation of osteocalcin 
is reportedly decreased in humans 
with insulin-resistant diabetes (Horiu-
chi et al., 2004). Third, the most com-
monly administered antiosteoporosis 
drugs, such as bisphosphonates, 
exert their effect by inhibiting the 
function of osteoclasts (the cells that 
resorb bone). Because bone remodel-
ing—an ever-occurring event respon-
sible for skeletal turnover—is charac-
terized by tethering of osteoclast and 
osteoblast activity, inhibition of bone 
formation follows osteoclast sup-
pression. In fact, decreased osteo-
calcin synthesis is a common conse-
quence of bisphosphonate therapy 
(Greenspan et al., 2005). Given the 
figure 1. effects of Bone on energy Metabolism
The Esp gene, also known as Ptprv, encodes a receptor-like protein phosphatase, OST-
PTP. Altering its expression has inverse effects on the metabolic bioactivity of osteocalcin, 
an osteoblast-specific protein. Increased osteocalcin metabolic bioactivity results in ben-
eficial effects in non-skeletal tissues, including improved pancreatic beta cell function and 
decreased adiposity.
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findings by Lee et al., (2007), a pos-
sible relationship between bisphos-
phonate therapy, glucose metabolism 
and adiposity should be explored. 
Finally, glucocorticoid therapy is 
common and predisposes patients 
to both diabetes and osteoporosis. 
Chronic administration of steroids 
affects osteoclasts and osteoblasts, 
suppressing bone formation and 
thus osteocalcin expression (Kim et 
al., 2006). Hence, it is possible that 
osteoporosis and diabetes, presently 
considered independent manifesta-
tions of glucocorticoid therapy, may 
be mechanistically linked.
Claude Bernard, the French physi-
ologist, is generally credited with the 
idea of homeostasis, which involves 
feedback regulation between dis-
tant cell types, the sine qua non of 
endocrinology. Beta cells and adi-
pocytes were known to talk to bone. 
Now, we learn that bone is talking 
back. The details of this conversa-
tion could identify new candidates 
for treating obesity, diabetes, and 
their complications.
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